HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Ramipril (Altace)

A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.

Also Known As:

Altace; Acovil; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Carasel; Delix; HOE-498; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramace; Triatec; Tritace; Vesdil; Zabien; HOE 498; HOE498; Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-

Networked: 995 relevant articles (118 outcomes, 420 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bicyclo Compounds
    - Ramipril: 995
      - ramiprilat: 49

Experts

1.	Yusuf, Salim: 42 articles (08/2015 - 01/2002)
2.	Sleight, Peter: 18 articles (06/2015 - 01/2002)
3.	Pogue, Janice: 15 articles (01/2015 - 01/2002)
4.	Teo, Koon: 14 articles (07/2015 - 07/2004)
5.	Lonn, Eva: 14 articles (03/2015 - 01/2002)
6.	Gao, Peggy: 13 articles (08/2015 - 10/2009)
7.	Teo, Koon K: 13 articles (08/2015 - 09/2004)
8.	Bosch, Jackie: 13 articles (08/2014 - 03/2002)
9.	Yusuf, S: 13 articles (04/2009 - 01/2000)
10.	Anderson, Craig: 11 articles (07/2015 - 07/2004)

Related Diseases

1.	Hypertension (High Blood Pressure) 07/01/2008 - "Ramipril also proved to be more effective in reducing the incidence of manifest office hypertension in patients with baseline ambulatory blood pressure monitoring high-normal blood pressure. " 08/01/2008 - "In conclusion, based on its efficacy and tolerability profile the combination of ramipril and HCT was shown to be effective therapy for the treatment of stage 2 hypertension." 08/01/2004 - "Ramipril appears to be an effective and safe antihypertensive and antiproteinuric agent in children with CRF-associated hypertension. " 05/01/2002 - "These results indicate that ACE inhibition by ramipril may be useful for the treatment of peripheral vascular complications in hypertension." 02/01/1993 - "Combination therapy with ramipril plus HCT was safe and effective for patients with mild-to-moderate essential hypertension."
2.	Proteinuria 11/01/2009 - "Clinical course was good but the patient developed proteinuria, which improved with ramipril. " 01/01/1997 - "It is inferred that ramipril is effective in the treatment of DN at the stage of microalbuminuria and proteinuria in patients with normal BP." 01/01/1996 - "The study suggests that ramipril ameliorates proteinuria independently of obvious glomerular histological changes. " 01/01/1997 - "All the patients with proteinuria and macroalbuminuria benefited from ramipril therapy because their proteinuria diminished or even disappeared (2 cases). " 04/01/1991 - "Ramipril treatment improved animal survival independently of a reduction in blood pressure or an effect on proteinuria. "
3.	Heart Failure 10/01/1995 - "These results strongly suggest that an overall improvement in heart failure was achieved after long-term ramipril therapy. " 07/01/2007 - "Ramipril has been used in twice daily dose of 5 mg in most heart failure trials, whereas the dose used in Heart Outcomes Prevention Evaluation (HOPE) study was 10 mg once at bedtime. " 05/01/2004 - "In the Heart Outcomes Prevention Evaluation (HOPE) study, ramipril was shown to reduce the risk for MI and other cardiovascular events in patients at high risk for pathological cardiac events, but without heart failure or a low ejection fraction. " 08/01/2002 - "Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study." 08/01/1999 - "We analysed retrospectively data from the AIRE study (randomised, placebo-controlled trial of ramipril in 2006 post-AMI patients with clinical heart failure). "
4.	Stroke (Strokes) 12/01/2002 - "Ramipril has been found to be effective in reducing stroke risk by 33% in diabetic patinets in HOPE study." 04/01/2003 - "Ramipril 10 mg/d was a cost-effective means of preventing first and recurrent ischemic strokes in the HOPE Study patient population." 04/01/2003 - "The purpose of this economic analysis was to estimate the potential economic benefits of the differences in direct health care costs attributable to the prevention of first and recurrent strokes in the HOPE Study patient population through the use of ramipril. " 04/01/2003 - "Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study." 01/01/2003 - "Results from the HOPE study, in which 9297 patients were randomized to receive either ramipril 10 mg/day or placebo for a mean of 4.5 years, indicate that ramipril reduced the relative risk of the composite outcome of MI, stroke and cardiovascular death by 22%. "
5.	Myocardial Infarction 05/01/2012 - "The current study aims to explore the effect of ramipril on the occurrence of ventricular arrhythmias and its possible mechanism after myocardial infarction (MI) in rabbits. " 01/20/2005 - "The present study was conducted to examine the combined effects of a chronic ACEI, ramipril, and a chronic Ang II type 1 receptor blocker, TCV116, on rat CHF after myocardial infarction (MI). " 05/22/2003 - "However, a meta-regression analysis of blood pressure reduction in >20 antihypertensive therapy outcome trials found that the reduction in myocardial infarction risk with ramipril observed in HOPE was consistent with the modest blood pressure reduction seen with that agent. " 05/22/2003 - "In the Heart Outcomes Prevention Evaluation (HOPE) study, ramipril treatment in high-risk patients was associated with a 20% reduction in the risk for myocardial infarction; mean reduction in blood pressure was 3 mm Hg for systolic blood pressure and 1 mm Hg for diastolic blood pressure. " 08/01/2002 - "Our study demonstrates a favorable effect of ramipril on the fibrinolytic system after thrombolysis associated with a lower rate of postinfarct ischemic events within the first days after myocardial infarction. "

Related Drugs and Biologics

1.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
2.	telmisartan (Micardis)
3.	Losartan (Cozaar)
4.	Enalapril
5.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
6.	Amlodipine (Norvasc)
7.	Angiotensins
8.	olmesartan medoxomil (Votum)
9.	irbesartan
10.	Captopril (Capoten)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
3.	Aftercare (After-Treatment)
4.	Oral Administration
5.	Continuous Positive Airway Pressure